Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Conditions
Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions
Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Inebilizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
La Jolla, California • Loma Linda, California • Boston, Massachusetts + 1 more
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Completed Phase 1Phase 2 Interventional Results available

Neuromyelitis Optica (NMO) & Cetirizine

NCT02865018
Conditions
Neuromyelitis Optica
Interventions
cetirizine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Recruiting No phase listed Observational Accepts healthy volunteers

MS-ResearchBiomarkerS

NCT05204459
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2041
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neuromyelitis Optica, Devic's Disease
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biobank For MS And Other Demyelinating Diseases

NCT00445367
Conditions
Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Other
Eligibility
Not listed
Enrollment
3,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2036
U.S. locations
10
States / cities
Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Blood tests, Inebilizumab
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Conditions
Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
Interventions
Mitoxantrone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Neuromyelitis Optica
Interventions
Alpha1-antitrypsin, methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Conditions
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interventions
Inebilizumab, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Conditions
Optic Neuritis
Interventions
Efgartigimod Alfa, Placebo
Drug
Lead sponsor
Anastasia Vishnevetsky, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
B-cell Mediated Autoimmune Disorders
Interventions
Azercabtagene zapreleucel (azer-cel)
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
Wellness Program and Behavioral Counseling
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Neuromyelitis Optica
Interventions
Ravulizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Completed No phase listed Observational

Pediatric NMOSD Observational Study

NCT03766347
Conditions
Neuromyelitis Optica, NMO Spectrum Disorder
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
NMOSD
Interventions
Rituximab (R), Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2021 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts